Previous 10 | Next 10 |
TherapeuticsMD (TXMD) has priced an underwritten public offering of 59.5 million shares for net proceeds of $110M.Proceeds to be used for commercialization of its three FDA-approved products, Imvexxy, Bijuva, and Annovera; partial proceeds also for offering to discharge certain indebtedness c...
TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced the pricing of its underwritten public offering of approximately 59.5 million shares of its common stock for gross proceeds of $110 million, before deducting the underwriting discounts and commissions and other estimated offering expens...
TherapeuticsMD (TXMD) announced an underwritten public offering with 30-day option granted to underwriters to purchase up to an additional 15% of shares.Shares were down 2.3% in after hours trade post the offering.Offer size, terms not yet disclosed.Proceeds to be used for commercia...
CRH Medical Corporation (CRHM) +158% on being acquired by WELL health in $300M deal.Nemaura Medical (NMRD) +72%.Ocugen (OCGN) +71% on $23M capital raise.Westport Fuel Systems (WPRT) +49%.Nxt-ID (NXTD) +43%.Tortoise Acquisition Corp. II (SNPR) +41% on deal to take Volta Industri...
Two of the most popular stocks on Robinhood's Top 100 list are TherapeuticsMD (NASDAQ: TXMD) and New Residential Investment (NYSE: NRZ) , both of which trade for under $10. The investment thesis for many excited investors is these stocks have a lot of room to grow. The probl...
The company has been burning significant cash, but the trend is finally changing. Annovera grew sales by 50% in Q3 which took the pressure off somewhat. TherepeuticsMD needs this growth to continue to turn the company around. For further details see: TherapeuticsMD: Anno...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that the company will participate at the following investor conferences: A live webcast and replay of the presentation can be accessed on the company’s website, www.therape...
Educational Campaign Will Help Empower Women to Have Open and Candid Conversations about Reproductive Health and Contraceptive Options Whitney Cummings Shares Her Experience Switching to ANNOVERA ® (segesterone acetate and ethinyl estradiol vaginal system) T...
TherapeuticsMD recently reported a strong Q3 earnings with a beat on EPS and revenue. The company was able to fight through the COVID-19 headwinds to surpass Q2's commercial numbers. It appears the company will be able to hit their Q4 revenue covenant with their lender. In addition, t...
News, Short Squeeze, Breakout and More Instantly...
TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Results Net Income (...
• Evaluation of strategic alternatives continues TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2023...